ADVANCED EPITHELIAL OVARIAN CANCER: THE PROGNOSTIC SIGNIFICANCE OF RESIDUAL DISEASE AFTER CYTOREDUCTIVE SURGERY | ||
| The Egyptian Journal of Surgery | ||
| Volume 21, Issue 4, October 2002, Pages 1032-1042 PDF (174.25 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejsur.2002.374948 | ||
| Authors | ||
| Ali El-Arini* 1; Ahmed Nabil Eissa2; Essam Shelbaya3; Khaled Kamal4 | ||
| 1Departments of General Surgery, Faculty of Medicine, Minoufiya University | ||
| 2Gynecology and Obstetrics, Faculty of Medicine, Minoufiya University | ||
| 3Department of General Surgery, Faculty of Medicine, Menya University | ||
| 4Nuclear Medicine, Faculty of Medicine, Minoufiya University | ||
| Abstract | ||
| Surgery remains the cornerstone of the treatment for epithelial ovarian cancer. For patients with advanced disease, the initial cytoreductive operation reduces tumor bulk and produces increased sensitivity to chemotherapy for the remaining tumor. The purpose of our study is to report the benefit of cytoreductive surgery by comparing patients with optimal residual disease ≤ 2cm, with those with suboptimal residual tumor >2cm. To assess the risk of operative complications and to identify determinants of survival. Patients and Methods: Between January 1998 and March 2002, 37 patients with FIGO stage II-IV underwent cytoreductive surgery followed by postoperative adjuvant cisplatin-based chemotherapy. A second-look laparotomy was performed in 15 patients (40.5%). The median follow-up was 18 months (range, 7-54). Results: Optimal cytoreduction to ≤ 2cm tumor deposits was performed in 16 cases (43.2%) and suboptimal cytoreduction to > 2cm residual tumors was performed in 21 cases (56.8%). The majority of patients had stage III disease (56.8%), serous epithelial ovarian cancer (67.6%), and moderately differentiated tumors (67.6%). Lymph nodes were positive in 15 cases (40.5%). Sixteen patients (43.2%) had positive cytology for ascites. CA-125 serum level was raised pre-operatively in 29 cases (78.4%). Postoperative complications occurred in 17 patients (45.9%). In our study population, advanced FIGO stage and high grade tumors acted as high-risk biologic markers in predicting suboptimal debulking. The overall median survival was 29 months, with overall 3-year survival of 40%. By multivariate analysis, only advanced FIGO stage, positive lymph nodes, and residual tumor deposits > 2cm remained significant for poor survival. Conclusion: Optimal cytoreduction in women with advanced epithelial ovarian cancer is associated with a more favorable outcome survival. | ||
| Keywords | ||
| Epithelial ovarian cancer; cytoreductive surgery; residual disease; survival | ||
|
Statistics Article View: 30 PDF Download: 25 |
||
